Last edition
News about
Johnson & Johnson’s IL-23 inhibitor becomes the first in its class to include evidence of structural joint damage inhibition in adults with active psoriatic arthritis.
A large-scale study involving more than 6,800 lymphoma patients found that CAR T-cell therapy delivered at non-FACT accredited centres achieved outcomes comparable to accredited facilities, supporting efforts to expand access to advanced cancer treatments closer to patients’ homes.
Abbott has received CE Mark approval for Libre Duo, the world’s first dual glucose-ketone sensing technology, offering continuous monitoring of both glucose and ketone levels to help prevent diabetic ketoacidosis and support safer diabetes care.
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.
Pfizer's LORBRENA Delivers 7-Year Progression-Free Survival in Advanced NSCLC
Pfizer reported 7-year results from the CROWN trial showing that LORBRENA achieved the longest Progression-Free Survival reported to date in advanced Non-Small Cell Lung Cancer (NSCLC), with 55 percent of patients remaining progression-free at 7 years and median progression-free survival not yet reached.
Antengene Corporation receives CDE endorsement to begin pivotal phase 3 CLINCH-3 study of ATG-022
Antengene has received approval from China’s Center for Drug Evaluation to initiate the pivotal Phase 3 CLINCH-3 study of ATG-022, advancing the development of its innovative antibody-drug conjugate for CLDN18.2-positive gastric cancers.
Tempus Wins FDA Approval for xT CDx, Expanding Solid Tumor Testing Portfolio
Tempus has received US FDA approval for its tumor-only xT CDx, becoming the first laboratory with companion diagnostic approval for both tumor-only and tumor-normal genomic profiling.
The World Health Organisation has issued its first recommendation on doxycycline Post-Exposure Prophylaxis (doxyPEP) for preventing bacterial STI, marking a significant step towards expanding evidence-based STI prevention options for vulnerable populations.
US FDA Approves DECNUPAZ for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
AbbVie has received US FDA approval for DECNUPAZ to treat adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), marking the first and only outpatient-initiated ADC for BPDCN and AbbVie’s first approved Antibody Drug Conjugate (ADC) for hematologic malignancies.
Alkem Reports Record FY26 EBITDA as Revenue Grows 13.5%; Q4 Profit Before Tax Rises 40.7 Percent
Alkem Laboratories posted its highest-ever EBITDA in FY26, driven by strong growth in domestic and international businesses, improved operating leverage, and disciplined cost management. The company also reported robust fourth-quarter performance, with revenue rising 14.6 percent and PBT before exceptional items increasing 40.7 percent YoY.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy